Related Experiment Video
Updated: Jul 9, 2026
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
A Simple Clinical Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with
Yang Liao1, Fei Wang2, Ting-Ting Tian2
1Department of Pediatrics, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Pudong, Shanghai, 201399, China. dr_liaoyang@163.com.
Objectives:
To develop and validate a simple, office-based screening tool for metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents with obesity using readily available clinical indicators.
Methods:
This cross-sectional study utilized NHANES 2021-2023 data (derivation cohort, n = 100) and 2017-2020 data (temporal validation cohort, n = 149). MASLD was defined as controlled attenuation parameter (CAP) ≥245 dB/m. Model performance was assessed using area under the receiver operating characteristic curve (AUC).
Results:
A simplified three-variable model incorporating alanine aminotransferase (ALT), triglycerides, and waist circumference demonstrated excellent discrimination (AUC 0.809, 95% CI: 0.721-0.897) in derivation and remained robust in validation (AUC 0.725, 95% CI: 0.636-0.814). Inclusion of homeostasis model assessment of insulin resistance (HOMA-IR) did not significantly improve performance (DeLong P >0.05).
Conclusions:
This validated three-parameter model requires no specialized tests or insulin measurement, providing a practical tool for frontline pediatricians to stratify MASLD risk during routine visits.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...